Hunan Dinuo Pharmaceutical Co. Ltd.

The loxoprofen sodium patch provided by Hunan Dino Pharmaceutical Co., Ltd. was used as the test formulation. Following bioequivalence testing regulations, the absorption rate and extent of the two formulations in healthy volunteers were compared with the reference formulation, loxoprofen sodium patch (trade name: Lesong®), licensed by Lead Chemical Co., Ltd., to investigate their bioequivalence. Secondary objectives: To investigate the safety, adhesion, and skin irritation of the test and reference formulations, loxoprofen sodium patches (trade name: Lesong®), in healthy volunteers.

Primary objective: This study aims to study the pharmacokinetic characteristics of a single topical application of crisaborole ointment (2% (30 g: 600 mg)) developed and produced by Hunan Dino Pharmaceutical Co., Ltd. in healthy study participants; Anacor Pharmaceuticals, Inc.'s licensed crisaborole ointment (Sultanmin®, each gram of this product contains 20 mg crisaborole (2%)) was used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation and the reference preparation after topical application in healthy study participants.

Primary objective: Orlistat capsules (specification: 60 mg) of Hunan Dino Pharmaceutical Co., Ltd. were used as the test preparation, and orlistat capsules (specification: 60 mg, trade name: Alli®) of GlaxoSmithKline Consumer Healthcare were used as the reference preparation. The pharmacodynamic differences between the two orlistat capsules were investigated. The bioequivalence of the two preparations was evaluated. Secondary objective: To observe the safety of repeated use of orlistat capsules in healthy study participants.